Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lyell Immunopharma, Inc. (LYEL : NSDQ)

• Company Description    Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 161

• Price / Volume Information    Yesterday's Closing Price: $17.46 Daily Weekly Monthly 20 Day Moving Average: 64,954 shares Shares Outstanding: 23.33 (millions) Market Capitalization: $407.41 (millions) Beta: -0.05 52 Week High: $45.00 52 Week Low: $7.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.02% -29.63% 12 Week -24.12% -29.85% Year To Date -43.28% -48.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 HASKINS WAY - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-695-0677 fax: - erose@lyell.com http://www.lyell.com

• General Corporate Information    Officers Lynn Seely - Chief Executive Officer and President Richard D. Klausner - Chairman Smital Shah - Chief Financial and Business Officer Mark Bachleda - Director Otis Brawley - Director Peer Information Lyell Immunopharma, Inc. (GSAC) Lyell Immunopharma, Inc. (CASIF) Lyell Immunopharma, Inc. (ALCD.) Lyell Immunopharma, Inc. (OMNN) Lyell Immunopharma, Inc. (CGPI.) Lyell Immunopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 55083R203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 23.33 Most Recent Split Date: 6.00 (0.05:1) Beta: -0.05 Market Capitalization: $407.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.49 Price/Cash Flow: - Price / Sales: 13,142.31 EPS Growth vs. Year Ago Period: 69.44% vs. Previous Quarter: 85.68% Sales Growth vs. Year Ago Period: -71.43% vs. Previous Quarter: -66.67% ROE 03/31/26 - -85.71 12/31/25 - -90.52 09/30/25 - -96.68 ROA 03/31/26 - -66.41 12/31/25 - -70.22 09/30/25 - -76.00 Current Ratio 03/31/26 - 7.23 12/31/25 - 5.28 09/30/25 - 10.30 Quick Ratio 03/31/26 - 7.23 12/31/25 - 5.28 09/30/25 - 10.30 Operating Margin 03/31/26 - -794,858.12 12/31/25 - -762,355.56 09/30/25 - -794,292.69 Net Margin 03/31/26 - -794,858.12 12/31/25 - -762,355.56 09/30/25 - -794,292.69 Pre-Tax Margin 03/31/26 - -794,858.06 12/31/25 - -762,355.56 09/30/25 - -794,292.69 Book Value 03/31/26 - 11.73 12/31/25 - 11.68 09/30/25 - 17.13 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©